Related references
Note: Only part of the references are listed.β1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension
Jie Liu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Influence of phenotype and pharmacokinetics on β-blocker drug target pharmacogenetics
A. L. Beitelshees et al.
PHARMACOGENOMICS JOURNAL (2006)
Influence of CYP2D6 genotype on metoprolol plasma concentration and β-adrenergic inhibition during long-term treatment -: A comparison with bisoprolol
T Nozawa et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol:: A prospective clinical study
R Fux et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Common variants in myocardial ion channel genes modify the QT interval in the general population -: Results from the KORA study
A Pfeufer et al.
CIRCULATION RESEARCH (2005)
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension
I Zineh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics
J Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects
H Wuttke et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment
T Rau et al.
PHARMACOGENETICS (2002)
Polymorphic deletion of three intracellular acidic residues of the α2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization
KM Small et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure
M Börjesson et al.
EUROPEAN HEART JOURNAL (2000)
Share Paper
